|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1299 Pennsylvania Avenue, NW |
Address2 | Suite 825 |
City | Washington |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 48736-12
|
||||||||
|
6. House ID# 345580000
|
TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Wendy Sussman, Vice President, U.S. Healthcare Government & Public Affairs |
Date | 10/21/2019 5:03:37 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
General discussions regarding Predictive Toxicology Roadmap
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Stephanie |
Frye |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CHM
16. Specific lobbying issues
General discussions regarding the 2020 National Defense Authorization Act and PFAs/PFOS chemicals
General discussions regarding the Chemical Facility Anti-Terrorism Standards Act reauthorization
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Stephanie |
Frye |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S. 1209: Reforming Evergreening and Manipulation that Extends Drug Years Act; all provisions of the bill
S. 1416: Affordable Prescriptions for Patients Act of 2019; all provisions of the bill
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mallori |
Merandino |
|
|
|
Thomas |
Roberge |
|
|
|
Wendy |
Sussman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 3: Lower Drug Costs Now Act of 2019; all provisions of the bill
H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019; all provisions of the bill
H.R. 1046: Medicare Negotiation and Competitive Licensing Act of 2019; all provisions of the bill
H.R. 2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act; all provisions of the bill
H.R. 2296: More Efficient Tools to Realize Information for Consumers (METRIC) Act; all provisions of the bill
S. 102: Prescription Drug Price Relief Act of 2019; all provisions of the bill
S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019; all provisions of the bill
S. 377: Medicare Negotiation and Competitive Licensing Act of 2019; all provisions of the bill
S. 447: Keep Americans Safe Act; all provisions of the bill
S. 1895: Lower Health Care Costs Act; all provisions of the bill
S. 2543: Prescription Drug Pricing Reduction Act of 2019; all provisions of the bill
General discussions regarding support for, and importance of, care giving
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mallori |
Merandino |
|
|
|
Thomas |
Roberge |
|
|
|
Wendy |
Sussman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 3: Lower Drug Costs Now Act of 2019; all provisions of the bill
H.R. 1046: Medicare Negotiation and Competitive Licensing Act of 2019; all provisions of the bill
S. 102: Prescription Drug Price Relief Act of 2019; all provisions of the bill
S. 377: Medicare Negotiation and Competitive Licensing Act of 2019; all provisions of the bill
S. 1391: Fair Accountability and Innovative Research Drug Pricing Act of 2019; all provisions of the bill
S. 2543: Prescription Drug Pricing Reduction Act of 2019; all provisions of the bill
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mallori |
Merandino |
|
|
|
Thomas |
Roberge |
|
|
|
Wendy |
Sussman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 3: Lower Drug Costs Now Act of 2019; all provisions of the bill
H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019; all provisions of the bill
H.R. 1035: Prescription Drug Price Transparency Act; all provisions of the bill
H.R. 2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act; all provisions of the bill
H.R. 2296: More Efficient Tools to Realize Information for Consumers (MICRA) Act; all provisions of the bill
S. 102: Prescription Drug Price Relief Act of 2019; all provisions of the bill
S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019; all provisions of the bill
S. 447: Keep Americans Safe Act; all provisions of the bill
S. 474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019; all provisions of the bill
S. 1209: Reforming Evergreening and Manipulation that Extends Drug Years Act; all provisions of the bill
S. 1391: Fair Accountability and Innovative Research Drug Pricing Act of 2019; all provisions of the bill
S. 1416 - Affordable Prescriptions for Patients Act of 2019; all provisions of the bill
S. 1895: Lower Health Care Costs Act; all provisions of the bill
S. 2543: Prescription Drug Pricing Reduction Act of 2019; all provisions of the bill
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mallori |
Merandino |
|
|
|
Thomas |
Roberge |
|
|
|
Wendy |
Sussman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAR
16. Specific lobbying issues
General discussions regarding the 2020 Miscellaneous Tariff Bill (MTB) process
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Stephanie |
Frye |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
General discussions regarding United States-Switzerland Trade Agreement
General discussions regarding United States-Mexico-Canada Agreement (USMCA)
General discussions regarding China Section 301 tariffs and product exclusions
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Stephanie |
Frye |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
General discussions regarding Predictive Toxicology Roadmap
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Stephanie |
Frye |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
General discussions regarding the repeal of Internal Revenue Code Section 385 regulations
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Stephanie |
Frye |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |